CF
ADMA icon

Corebridge Financial’s ADMA Biologics ADMA Stock Holding History

Corebridge Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-120,160
Closed -$2.38M – 51
2025
Q1 		$2.38M Sell
120,160
-139
-0.1% -$2.4K 0.01% 919
2024
Q4 		$2.06M Sell
120,299
-9,277
-7% -$175K 0.01% 1006
2024
Q3 		$2.59M Buy
129,576
+8,417
+7% +$131K 0.01% 944
2024
Q2 		$1.35M Buy
+121,159
New +$1.02M 0.01% 1174

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Corebridge Financial's ADMA Position: Q2 2025 in Review

Corebridge Financial sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 120,160 shares — an estimated $2.38M sold.

Corebridge Financial first reported a position in ADMA in Q2 2024 and held it in 4 quarters. The position peaked at $2.59M in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Corebridge Financial reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 120,160 ADMA Biologics shares in Q2 2025, an estimated $2.38M.
  • Corebridge Financial first reported a position in ADMA Biologics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ADMA Biologics position peaked at $2.59M in Q3 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.